Keywords: مقاومت ترستوزوماب; Androgen receptor expression; HER2-positive metastatic breast cancer; Immune cell infiltration; Trastuzumab resistance;
مقالات ISI مقاومت ترستوزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer
Keywords: مقاومت ترستوزوماب; HER2; p95HER2; Flubendazole; Cancer stem cells; Trastuzumab resistance;
HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
Keywords: مقاومت ترستوزوماب; Gold nanoparticle; Trastuzumab resistance; HER2; Gastric cancer; Autophagy; Tmab; trastuzumab; HER2; human epidermal growth factor receptor 2; AuNP; gold nanoparticle; ECD; extracellular domain; ADCC; antibody-dependent cellular cytotoxicity; PTEN; phosph
Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer
Keywords: مقاومت ترستوزوماب; HER2; p95HER2; Disulfiram; ALDH1A1; Apoptosis; Trastuzumab resistance
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation
Keywords: مقاومت ترستوزوماب; Uterine serous carcinoma; HER2; Ridaforolimus; Trastuzumab resistance; mTOR inhibition; Rapalog
Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer
Keywords: مقاومت ترستوزوماب; Breast cancer; Saracatinib; Anti-ErbB2 antibody; Cell death; Trastuzumab resistance;
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant
Keywords: مقاومت ترستوزوماب; High grade endometrial carcinoma; HER2 over-expression; p95HER2; Trastuzumab resistance;
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
Keywords: مقاومت ترستوزوماب; Targeted therapy; Combination approaches; HER2-positive breast cancer; Trastuzumab resistance;
Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance
Keywords: مقاومت ترستوزوماب; Erbin; Her2; AKT; Breast cancer; Cell migration; Trastuzumab resistance
Advanced HER2-positive gastric cancer: Current and future targeted therapies
Keywords: مقاومت ترستوزوماب; Gastric cancer; Human epidermal growth factor receptor; Trastuzumab resistance; Multitargeted tyrosine kinase inhibitors; Second line therapies; Targeted therapies
Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells
Keywords: مقاومت ترستوزوماب; Trastuzumab resistance; Rac1; PTEN; IGF-IR; Akt; HER2
Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress
Keywords: مقاومت ترستوزوماب; CXB, celecoxib (Celebrex®); DMC, 2,5-dimethyl-celecoxib; NFV, nelfinavir (Viracept®); UMC, unmethylated-celecoxibGRP78; CHOP; GADD153; Doxorubicin resistance; Paclitaxel resistance; Trastuzumab resistance; Endoplasmic reticulum stress; Breast cancer; Drug
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor
Keywords: مقاومت ترستوزوماب; Circulating tumor cells; Disseminated tumor cells; Trastuzumab resistance; ErbB2/HER2; Breast tumor xenografts
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Keywords: مقاومت ترستوزوماب; ErbB1; ErbB2; EGFR; Tumor therapy/cancer therapy; Humanized antibody; Engineered antibody; Antibody targeted delivery; Antibody conjugation; Clinical trial; Trastuzumab resistance
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer
Keywords: مقاومت ترستوزوماب; ErbB2; Trastuzumab resistance; CD44; Hyaluronan; Masking